Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26547297 | 0.90 | EPHX2 (0.39) | EPHX2HTR2AHTR2CHTR2BGAA | |
| SCHEMBL7017304 | 0.79 | MEN1 (0.50) | EPHX2MEN1RAB9AGFERKMT2A | |
| SCHEMBL26547286 | 0.76 | BRD4 (0.39) | MEN1RAB9AGFERKMT2AGAA | |
| SCHEMBL26547288 | 0.75 | MEN1 (0.37) | EPHX2MEN1RAB9AGFERKMT2A | |
| SCHEMBL6980295 | 0.74 | HDAC6 (0.40) | KMT2AHTR2AHTR2CHTR2B | |
| SCHEMBL19754380 | 0.73 | HDAC6 (0.40) | KMT2AHTR2AHTR2CHTR2BCYP1A2 | |
| SCHEMBL12405333 | 0.71 | MEN1 (0.38) | EPHX2MEN1RAB9AGFERKMT2A | |
| SCHEMBL12049049 | 0.70 | MTNR1A (0.43) | EPHX2HTR2AHTR2CHTR2BCYP1A2 | |
| SCHEMBL11584126 | 0.70 | EPHX2 (0.41) | EPHX2GAA | |
| SCHEMBL26549764 | 0.70 | CYP2D6 (0.37) | MEN1KMT2ACYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322724-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322724-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | EP300, HDAC1, BRD3 | EPHX2 1846/4885MEN1 2797/4885RAB9A 3660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.